Development of red blood cell-derived extracellular particles as a biocompatible nanocarrier of microRNA-204 (REP-204) to harness anti-neuroblastoma effect
Issued Date
2024-08-01
Resource Type
ISSN
15499634
eISSN
15499642
Scopus ID
2-s2.0-85195378528
Journal Title
Nanomedicine: Nanotechnology, Biology, and Medicine
Volume
60
Rights Holder(s)
SCOPUS
Bibliographic Citation
Nanomedicine: Nanotechnology, Biology, and Medicine Vol.60 (2024)
Suggested Citation
Chiangjong W., Panachan J., Keadsanti S., Newburg D.S., Morrow A.L., Hongeng S., Chutipongtanate S. Development of red blood cell-derived extracellular particles as a biocompatible nanocarrier of microRNA-204 (REP-204) to harness anti-neuroblastoma effect. Nanomedicine: Nanotechnology, Biology, and Medicine Vol.60 (2024). doi:10.1016/j.nano.2024.102760 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/98782
Title
Development of red blood cell-derived extracellular particles as a biocompatible nanocarrier of microRNA-204 (REP-204) to harness anti-neuroblastoma effect
Corresponding Author(s)
Other Contributor(s)
Abstract
Neuroblastoma (NB) is the most common extracranial solid tumor in the pediatric population with a high degree of heterogeneity in clinical outcomes. Upregulation of the tumor suppressor miR-204 in neuroblastoma is associated with good prognosis. Although miR-204 has been recognized as a potential therapeutic candidate, its delivery is unavailable. We hypothesized that REP-204, the red blood cell-derived extracellular particles (REP) with miR-204 loading, can suppress neuroblastoma cells in vitro. After miR-204 loading by electroporation, REP-204, but not REP carriers, inhibited the viability, migration, and 3D spheroid growth of neuroblastoma cells regardless of MYCN amplification status. SWATH-proteomics revealed that REP-204 treatment may trigger a negative regulation of mRNA splicing by the spliceosome, suppression of amino acid metabolism and protein production, and prevent SLIT/ROBO signaling-mediated cell migration, to halt neuroblastoma tumor growth and metastasis. The therapeutic efficacy of REP-204 should be further investigated in preclinical models and clinical studies.